The growth in Artificial Intelligence (AI) has proliferated into various sectors. A lot of startups across the world are creating new approaches and seeking after the inventive business models in a bid to alter the pharmaceutical businesses.
London-based drug discovery company, LabGenius has announced today that it has raised over $10 million (€11.5 million) in its Series A financing round. LabGenius is a drug discovery company that is using artificial intelligence (AI), robotic automation, and synthetic biology to discover novel protein therapeutics.